The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin - Rapid communication

被引：37
|
作者：
Martin, P
Waters, N
Carlsson, A
Carlsson, ML
机构：
[1] Department of Pharmacology, Göteborg University
[2] Department of Pharmacology, Göteborg University, S-413 90 Göteborg
来源：
JOURNAL OF NEURAL TRANSMISSION | 1997年 / 104卷 / 4-5期
关键词：
MK-801; locomotion; ritanserin; M100907;
D O I：
10.1007/BF01277672
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The apparent antipsychotic action of the selective 5-HT2a receptor antagonist M100907 in MK-801-treated NMRI mice was shown to be markedly counteracted by the 5-HT2a/2c receptor antagonist ritanserin. The mechanism of action and potential implications are discussed.
引用
收藏
页码：561 / 564
页数：4
相关论文
共 50 条
  • [1] The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin
    P. Martin
    N. Waters
    A. Carlsson
    M. L. Carlsson
    Journal of Neural Transmission, 1997, 104 : 561 - 564
  • [2] Comparison of 5-HT2A antagonists M100907 and ritanserin in preclinical models of antipsychotic activity
    Sorensen, SM
    Martin, P
    Hitchcock, JM
    SCHIZOPHRENIA RESEARCH, 1998, 29 (1-2) : 170 - 170
  • [3] 5-HT2A receptor antagonist M100907 reduces serotonin synthesis: An autoradiographic study
    Hasegawa, Shu
    Fikre-Merid, Maraki
    Diksic, Mirko
    BRAIN RESEARCH BULLETIN, 2012, 87 (01) : 44 - 49
  • [4] The 5-HT2A receptor antagonist M100907 produces antiparkinsonian effects and decreases striatal glutamate
    Ansah, Twum A.
    Ferguson, Marcus C.
    Nayyar, Tultul
    FRONTIERS IN SYSTEMS NEUROSCIENCE, 2011, 5
  • [5] Actions of the 5-HT2A antagonist M100907 in serotonin-depleted mice
    Fantegrossi, WE
    Kilbourn, M
    Woods, JH
    FASEB JOURNAL, 2004, 18 (05): : A965 - A965
  • [6] MDL-100907 -: Antipsychotic -: 5-HT2A Antagonist
    不详
    DRUGS OF THE FUTURE, 2000, 25 (09) : 975 - 977
  • [7] Synthesis and activity of functionalizable derivatives of the serotonin (5-HT) 5-HT2A receptor (5-HT2AR) antagonist M100907
    Gilbertson, Scott R.
    Chen, Ying-Chu
    Soto, Claudia A.
    Yang, Yaxing
    Rice, Kenner C.
    Cunningham, Kathryn A.
    Anastasio, Noelle C.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (08) : 1381 - 1385
  • [8] The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist than dopamine agonist induced hyperactivity in mice
    Carlsson, ML
    Martin, P
    Nilsson, M
    Sorensen, SM
    Carlsson, A
    Waters, S
    Waters, N
    JOURNAL OF NEURAL TRANSMISSION, 1999, 106 (02) : 123 - 129
  • [9] Clinical and pet effects of M100907, a selective 5HT-2A receptor antagonist
    Potkin, SG
    Shipley, J
    Bera, RB
    Carreon, D
    Fallon, J
    Alva, G
    Keator, D
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 242 - 242
  • [10] The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine
    Marek, GJ
    Martin-Ruiz, R
    Abo, A
    Artigas, F
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 (12) : 2205 - 2215
12345